Abstract Number: 1598 • ACR Convergence 2020
Efficacy of Universal Depression Screening in a Rheumatology Clinic
Background/Purpose: Depression has long been viewed as a comorbid condition in rheumatic diseases. Population studies have confirmed an increased incidence in patients with rheumatoid arthritis,…Abstract Number: 0194 • ACR Convergence 2020
Depression Symptoms but Not Clinically Diagnosed Depression Predict Mortality in Rheumatoid Arthritis
Background/Purpose: Depression and depressive symptoms are common but under-recognized in rheumatoid arthritis (RA). Few studies have examined depression symptoms in RA patients compared to clinically…Abstract Number: 1733 • ACR Convergence 2020
Patients with Rheumatoid Arthritis and Comorbid Depression Have High Levels of RAPID3 (Routine Assessment of Patient Index Data) and FAST3 (Fibromyalgia Assessment Screening Index) on a Multidimensional Health Assessment Questionnaire (MDHAQ)
Background/Purpose: Patients with rheumatoid arthritis (RA) have higher comorbid depression and/or fibromyalgia (FM) than the general population. A multidimensional health-assessment questionnaire (MDHAQ) includes two queries…Abstract Number: 0336 • ACR Convergence 2020
Anxiety and Depression in Psoriatic Arthritis (PsA) – Prevalence and Impact on Patient Reported Outcomes: Real-World Survey in the US and Europe
Background/Purpose: Anxiety and depression are comorbidities among PsA patients. The impact of anxiety and depression on outcomes in PsA patients has not been characterized in…Abstract Number: 1737 • ACR Convergence 2020
What Influences Fatigue Improvement in Rheumatoid Arthritis? A Prospective Cohort Study
Background/Purpose: Fatigue is a common and debilitating complication in patients with rheumatoid arthritis (RA). Its mechanism is not fully elucidated, and when persistent is often…Abstract Number: 0434 • ACR Convergence 2020
Changes in Mental Health During the COVID-19 Pandemic Among Individuals with Rheumatic Disease
Background/Purpose: Symptoms of both depression and anxiety are often elevated among individuals with rheumatic conditions, and stress levels may play a role in each. Depression,…Abstract Number: 1804 • ACR Convergence 2020
Impact of the Kynurenine/Tryptophan Pathway on Cognitive Dysfunction and Depression in Systemic Lupus Erythematosus
Background/Purpose: Tryptophan (TRP) is metabolized to kynurenine (KYN), quinolonic acid [QA, a N-methyl D-aspartate receptor (NMDAR) agonist] and kynurenic acid (KA, an NMDAR antagonist). KYN/TRP…Abstract Number: 006 • 2020 Pediatric Rheumatology Symposium
Increasing Rates of Standardized Depression Screening in Youth with Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic
Background/Purpose: Depression is common among youth with SLE. Early identification and treatment of depression has the potential to improve health outcomes for youth with SLE.…Abstract Number: 049 • 2020 Pediatric Rheumatology Symposium
Levels of Anxiety and Depressive Symptoms in Juvenile Idiopathic Arthritis (JIA) and Their Correlation to Disease Manifestations Using Patient-Reported Outcomes Measurement Information System (PROMIS®) Measures
Background/Purpose: Children with chronic diseases have higher rates of mental health issues and less favorable outcomes than the general pediatric population. Children with JIA experience…Abstract Number: 134 • 2020 Pediatric Rheumatology Symposium
Evaluation of Self-report Screening Measures in the Detection of Depressive and Anxiety Disorders Among Children and Adolescents with Systemic Lupus Erythematosus
Background/Purpose: Screening for co-morbid psychiatric disorder is of high clinical importance in childhood-onset systemic lupus erythematosus (cSLE). However, there are no validated screening measures for…Abstract Number: 1341 • 2019 ACR/ARP Annual Meeting
Impact of Tocilizumab on Anxiety and Depression in Patients with Rheumatoid Arthritis
Background/Purpose: Mood disorders, such as anxiety and depression are extremely prevalent amongst patients with rheumatoid arthritis (RA). In this study we sought to assess the…Abstract Number: 1414 • 2019 ACR/ARP Annual Meeting
Improvement of Mental Health and Quality of Life During Therapy with Tocilizumab
Background/Purpose: In rheumatoid arthritis (RA), the proinflammatory cytokine IL-6 is associated with mental disorders such as depression and anxiety.1 Furthermore, depression and anxiety are comorbidities…Abstract Number: 1444 • 2019 ACR/ARP Annual Meeting
Tofacitinib in Patients with Rheumatoid Arthritis and Indicative of Depression And/or Anxiety: A Post Hoc Analysis of Phase 3 and Phase 3b/4 Clinical Trials
Background/Purpose: Depression and anxiety are common in patients (pts) with RA1 and can lead to reduced quality of life, functional capacity, and RA treatment response.2-4…Abstract Number: 1490 • 2019 ACR/ARP Annual Meeting
Blockage of TNFα and IL-12/23 Improves Depressive Symptoms in Patients with Psoriatic Arthritis – Analysis of Clinical Trial Data
Background/Purpose: The prevalence of depression is increased in patients with psoriatic arthritis (PsA). Little is known about the impact of effective control of inflammation on…Abstract Number: 2822 • 2019 ACR/ARP Annual Meeting
Depression and Subsequent Risk for Incident Seronegative Rheumatoid Arthritis Among Women
Background/Purpose: Depression is associated with elevated systemic inflammation and risk of several chronic diseases including lupus, psoriasis, and inflammatory bowel disease. However, the association between…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 15
- Next Page »